Additionally, in line with its therapeutic potential, Bos@nanoMIL-89 resulted in a substantial decrease in endothelin-1 (ET-1) levels, a key mediator of vasoconstriction and vascular remodeling in PAH. The gene discussed is EDN1; the disease is pulmonary arterial hypertension.